|
1
|
Kumar M, Zhao X and Wang XW: Molecular
carcinogenesis of hepatocellular carcinoma and intrahepatic
cholangiocarcinoma: One step closer to personalized medicine? Cell
Biosci. 1:52011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Diaz-Gonzalez A, Forner A, de Lope
Rodriguez C and Varela M: New challenges in clinical research on
hepatocellular carcinoma. Rev Esp Enferm Dig. 108:485–493.
2016.PubMed/NCBI
|
|
3
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al: Global surveillance of cancer survival 1995–2009: Analysis
of individual data for 25 676 887 patients from 279
population-based registries in 67 countries (CONCORD-2). Lancet.
385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: A global and regional perspective. Oncologist. 15 Suppl
4:S5–S13. 2010. View Article : Google Scholar
|
|
6
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu M, Jiang L and Guan XY: The genetic
and epigenetic alterations in human hepatocellular carcinoma: A
recent update. Protein Cell. 5:673–691. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rasool M, Rashid S, Arooj M, Ansari SA,
Khan KM, Malik A, Naseer MI, Zahid S, Manan A, Asif M, et al: New
possibilities in hepatocellular carcinoma treatment. Anticancer
Res. 34:1563–1571. 2014.PubMed/NCBI
|
|
10
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park US, Park SK and Lee YI, Park JG and
Lee YI: Hepatitis B virus-X protein upregulates the expression of
p21waf1/cip1 and prolongs G1->S transition via a p53-independent
pathway in human hepatoma cells. Oncogene. 19:3384–3394. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arbuthnot P, Capovilla A and Kew M:
Putative role of hepatitis B virus X protein in
hepatocarcinogenesis: Effects on apoptosis, DNA repair,
mitogen-activated protein kinase and JAK/STAT pathways. J
Gastroenterol Hepatol. 15:357–368. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aravalli RN, Steer CJ and Cressman EN:
Molecular mechanisms of hepatocellular carcinoma. Hepatology.
48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Macintyre AN and Rathmell JC: PKM2 and the
tricky balance of growth and energy in cancer. Mol Cell.
42:713–714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garnett ME, Dyson RD and Dost FN: Pyruvate
kinase isozyme changes in parenchymal cells of regenerating rat
liver. J Biol Chem. 249:5222–5226. 1974.PubMed/NCBI
|
|
17
|
Lu Z: Nonmetabolic functions of pyruvate
kinase isoform M2 in controlling cell cycle progression and
tumorigenesis. Chin J Cancer. 31:5–7. 2012.PubMed/NCBI
|
|
18
|
Yang W, Xia Y, Hawke D, Li X, Liang J,
Xing D, Aldape K, Hunter T, Yung Alfred WK and Lu Z: PKM2
phosphorylates histone H3 and promotes gene transcription and
tumorigenesis. Cell. 150:685–696. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong CC, Au SL, Tse AP, Xu IM, Lai RK,
Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, et al: Switching of
pyruvate kinase isoform L to M2 promotes metabolic reprogramming in
hepatocarcinogenesis. PLoS One. 9:e1150362014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng XC, Gong FM, Zhao YW, Zhou LX, Xie
YW, Liao HL, Lin HJ, Li ZY, Tang MH and Tong AP: Comparative
proteomic approach identifies PKM2 and cofilin-1 as potential
diagnostic, prognostic and therapeutic targets for pulmonary
adenocarcinoma. PLoS One. 6:e273092011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar Y, Tapuria N, Kirmani N and Davidson
BR: Tumour M2-pyruvate kinase: A gastrointestinal cancer marker.
Eur J Gastroenterol Hepatol. 19:265–276. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Landt S, Jeschke S, Koeninger A, Thomas A,
Heusner T, Korlach S, Ulm K, Schmidt P, Blohmer JU, Lichtenegger W,
et al: Tumor-specific correlation of tumor M2 pyruvate kinase in
pre-invasive, invasive and recurrent cervical cancer. Anticancer
Res. 30:375–381. 2010.PubMed/NCBI
|
|
23
|
Haug U, Hundt S and Brenner H: Sensitivity
and specificity of faecal tumour M2 pyruvate kinase for detection
of colorectal adenomas in a large screening study. Br J Cancer.
99:133–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu H, Luo H and Zhu X, Hu X, Zheng L and
Zhu X: Pyruvate kinase M2 (PKM2) expression correlates with
prognosis in solid cancers: A meta-analysis. Oncotarget.
8:1628–1640. 2017.PubMed/NCBI
|
|
25
|
Alves-Filho JC and Palsson-McDermott EM:
Pyruvate Kinase M2: A potential target for regulating inflammation.
Front Immunol. 7:1452016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu DH, Yu HQ, Wang Q, Liu JT and Sun GP:
Expression of pyruvate kinase M2 in hepatocellular carcinoma and
its clinical significance. Anhui Med Pharma. 20:707–710. 2016.(In
Chinese).
|
|
27
|
Liu Y, Wu H, Mei Y, Ding X, Yang X, Li C,
Deng M and Gong J: Clinicopathological and prognostic significance
of PKM2 protein expression in cirrhotic hepatocellular carcinoma
and non-cirrhotic hepatocellular carcinoma. Sci Rep. 7:152942017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen
D, Chen T, Li J, Fan J, Cong W, et al: Co-expression of PKM2 and
TRIM35 predicts survival and recurrence in hepatocellular
carcinoma. Oncotarget. 6:2538–2548. 2015.PubMed/NCBI
|
|
29
|
Liu WR, Tian MX, Yang LX, Lin YL, Jin L,
Ding ZB, Shen YH, Peng YF, Gao DM, Zhou J, et al: PKM2 promotes
metastasis by recruiting myeloid-derived suppressor cells and
indicates poor prognosis for hepatocellular carcinoma. Oncotarget.
6:846–861. 2015.PubMed/NCBI
|
|
30
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eggert T, McGlynn KA, Duffy A, Manns MP,
Greten TF and Altekruse SF: Epidemiology of fibrolamellar
hepatocellular carcinoma in the USA, 2000–10. Gut. 62:1667–1668.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47 Suppl:S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kefas B, Comeau L, Erdle N, Montgomery E,
Amos S and Purow B: Pyruvate kinase M2 is a target of the
tumor-suppressive microRNA-326 and regulates the survival of glioma
cells. Neuro Oncol. 12:1102–1112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi HS, Li D, Zhang J, Wang YS, Yang L,
Zhang HL, Wang XH, Mu B, Wang W, Ma Y, et al: Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts
in mice. Cancer Sci. 101:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Israelsen WJ, Dayton TL, Davidson SM,
Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW,
et al: PKM2 isoform-specific deletion reveals a differential
requirement for pyruvate kinase in tumor cells. Cell. 155:397–409.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang YH, Israelsen WJ, Lee D, Yu VW,
Jeanson NT, Clish CB, Cantley LC, Vander Heiden MG and Scadden DT:
Cell-state-specific metabolic dependency in hematopoiesis and
leukemogenesis. Cell. 158:1309–1323. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang W, Xia Y, Ji H, Zheng Y, Liang J,
Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates β-catenin
transactivation upon EGFR activation. Nature. 480:118–122. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao X, Zhao L, Yang H, Li J, Min X, Yang
F, Liu J and Huang G: Pyruvate kinase M2 interacts with nuclear
sterol regulatory element-binding protein 1a and thereby activates
lipogenesis and cell proliferation in hepatocellular carcinoma. J
Biol Chem. 293:6623–6634. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu J, Hu L, Chen M, Cao W, Chen H and He
T: Pyruvate kinase M2 overexpression and poor prognosis in solid
tumors of digestive system: evidence from 16 cohort studies. Onco
Targets Ther. 9:4277–4288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dayton TL, Gocheva V, Miller KM, Israelsen
WJ, Bhutkar A, Clish CB, Davidson SM, Luengo A, Bronson RT, Jacks
T, et al: Germline loss of PKM2 promotes metabolic distress and
hepatocellular carcinoma. Genes Dev. 30:1020–1033. 2016. View Article : Google Scholar : PubMed/NCBI
|
